The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.
 
Salvatore Siena
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; CheckmAb; Daiichi Sankyo; Incyte; Merck; Novartis; Roche; Seagen
 
Andrea Sartore-Bianchi
No Relationships to Disclose
 
Nicola Personeni
No Relationships to Disclose
 
Filippo Pietrantonio
No Relationships to Disclose
 
Giovanni Germano
Stock and Other Ownership Interests - NeoPhore
 
Alessio Amatu
No Relationships to Disclose
 
Emanuela Bonoldi
No Relationships to Disclose
 
Emanuele Valtorta
No Relationships to Disclose
 
Ludovic Barault
No Relationships to Disclose
 
Federica Di Nicolantonio
Research Funding - Trovagene (Inst)
Patents, Royalties, Other Intellectual Property - Submitted patent application of the use of circulating methylated markers for colorectal cancer (Inst)
 
Giulia Siravegna
No Relationships to Disclose
 
Giovanni Crisafulli
No Relationships to Disclose
 
Lorenza Rimassa
Honoraria - Abbvie; AstraZeneca; Gilead Sciences; Roche
Consulting or Advisory Role - Amgen; ArQule; Baxter; Bayer; Celgene; Eisai; Exelixis; Incyte; Ipsen; Italfarmaco; Lilly; Sanofi; Sirtex Medical
Travel, Accommodations, Expenses - ArQule; Ipsen
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Dompè; Ignyta; Incyte; Novartis; Octimet; Pfizer; Pierre Fabre; Roche; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Roche
 
Armando Santoro
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; MSD; Pfizer; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Celgene; Lilly; Novartis; Roche; Sandoz; Takeda
 
Luca Lazzari
No Relationships to Disclose
 
Paolo Luraghi
No Relationships to Disclose
 
Nabil Amirouchene-Angelozzi
No Relationships to Disclose
 
Alberto Bardelli
Stock and Other Ownership Interests - NeoPhore; Phoremost
Honoraria - Guardant Health; Illumina; Merck; Novartis; Roche
Consulting or Advisory Role - Biocartis; Horizon Discovery; NeoPhore
 
Silvia Marsoni
Consulting or Advisory Role - Ignyta; Merrimack; Roche